In vivo age-related changes in hepatic drug-oxidizing capacity in humans

Journal of Clinical Pharmacy and Therapeutics

Volumn 23, Issue 4, 1998, Pages 247-255

  Tanaka, E ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 2C9; DIMETHYLNITROSAMINE DEMETHYLASE; IBUPROFEN; LIDOCAINE; MIDAZOLAM; NORTRIPTYLINE; PARACETAMOL; PHENACETIN O DEETHYLASE; PHENYTOIN; TERFENADINE; THEOPHYLLINE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; AGING; CHILD; CONTROLLED STUDY; DRUG OXIDATION; HUMAN; INFANT; LIVER METABOLISM; NEWBORN; REVIEW;

AGING; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOMERISM;

EID: 0031783832     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1998.00164.x     Document Type: Review

References (100)

1. Kearns GL, Reed MD. (1984) Clinical pharmacokinetics in infants and children. Clinical Pharmacokinetics, 17(Suppl. 1), 29-67.
2. Guengerich FP. (1984) Characterization of human microsomal cytochrome P-450 enzymes. Annual Review of Pharmacology and Toxicology, 29, 241-264.
3. Guengerich FP, Shimada T. (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology, 4, 391-407.
4. Gonzalez FJ, Gelboin HV. (1991) Human cytochrome P450: evolution, catalytic activities and interindividual variations in expression. Progress in Clinical and Biological Research, 372, 11-20.
5. Rane A, Sajšqvist F. (1972) Drug metabolism in the human fetus and newborn infant. Pediatric Clinics of North America, 19, 37-49.
6. Triggs EJ, Nation R. (1975) Pharmacokinetics in the aged: a review. Journal of Pharmacokinetics and Biopharmaceutics, 3, 387-418.
7. Crooks J, O'Malley K, Stevenson LH. (1976) Pharmacokinetics in the elderly. Clinical Pharmacokinetics, 1, 280-296.
8. Morselli PL, Franco-Morselli R, Bossi L. (1980) Clinical pharmacokinetics in newborns and infants. Clinical Pharmacokinetics, 5, 485-527.
9. Triggs EJ, Hooper WD, Dickinson RG. (1984) The influence of age on drug metabolism. The Medical Journal of Australian, 22, 823-827.
10. Schmucker DL. (1485) Ageing and drug disposition: an update. Pharmacological Reviews, 37, 133-148.
11. Cusack BJ. (1988) Drug metabolism in the elderly. Journal of Clinical Pharmacology, 28, 571-576.
12. Besunder JB, Reed MD, Blumer JL. (1988) Principles of drug biodisposition in the neonate: a critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I). Clinical Pharmacokinetics, 14, 189-216.
13. Besunder JB, Reed MD, Blumer JL. (1988) Principles of drug biodisposition in the neonate: a critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II). Clinical Pharmacokinetics, 14, 261-286.
14. Boreus LO. (1989) The role of therapeutic drug monitoring in children. Clinical Pharmacokinetics, 17(Suppl. 1), 4-12.
15. Morselli PL. (1989) Clinical pharmacology of the perinatal period and early infancy. Clinical Pharmacokinetics, 17(Suppl. 1), 13-28.
16. Kearns GL, Reed MD. (1989) Clinical pharmacokinetics in infants and children. Clinical Pharmacokinetics, 17(Suppl. 1), 29-67.
17. Durnas C, Loi CM, Cusack BJ. (1990) Hepatic drug metabolism and ageing. Clinical Pharmacokinetics, 19, 359-389.
18. Krauer B, Dayer P. (1991) Fetal drug metabolism and its possible clinical implications. Clinical Pharmacokinetics, 21, 70-80.
19. Woodhouse K, Wynne HA. (1992) Age-related changes in hepatic function. Drugs and Ageing, 2, 243-255.
20. Murray M. (1992) P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clinical Pharmacokinetics, 23, 132-146.
21. Milsap RL, Jusko WJ. (1994) Pharmacokinetics in the infant. Environmental Health Perspectives, 102(Suppl. 11), 107-110.
22. Crom WR. (1994) Pharmacokinetics in the child. Environmental Health Perspectives, 102(Suppl. 11), 111-118.
23. Gonzalez FJ, Idle JR. (1994) Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clinical Pharmacokinetics, 26, 59-70.
24. Kearns GL. (1995) Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes. Current Opinion in Pediatrics, 7, 220-233.
25. Bertilsson L. (1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clinical Pharmacokinetics, 29, 192-209.
26. Kinirons MT, Crome P. (1997) Clinical pharmacokinetics considerations in the elderly. Clinical Pharmacokinetics, 33, 302-312.
27. Le Couteur DG, McLean AJ. (1998) The ageing liver. Clinical Pharmacokinetics, 34, 359-373.
28. Hakkola J, Tanaka E, Pelkonen O. (1998) Developmental expression of cytochrome P450 enzymes in the human liver. Pharmacology and Toxicology, 82, 209-217.
29. Fuhr U, Rost KL. (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and saliva. Pharmacogenetics, 4, 109-116.
30. Rasmussen BB, Maenpaa J, Pelkonen O, et al. (1995) Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. British Journal of Clinical Pharmacology, 39, 151-159.
31. Aranda JV, Sitar DS, Parsons WD, Loughnan PM, Neims AH. (1976) Pharmacokinetic aspects of theophylline in premature newborns. New England Journal of Medicine, 295, 413-416.
32. Giacoia C, Jusko WJ, Menke J, Koup JR. (1976) Theophylline pharmacokinetics in premature infants with apnea. Journal of Pediatrics, 89, 829-832.
33. Neese AL, Soyka LF. (1977) Development of a radioimmunoassay for theophylline: application to studies in premature infants. Clinical Pharmacology and Therapeutics, 21, 633-641.
34. Latini R, Assael BM, Bonati M, et al. (1978) Kinetics and efficacy of theophylline in the treatment of apnea in the premature newborn. European Journal of Clinical Pharmacology, 13, 203-207.
35. Gabriel M, Witlla C, Albani M. (1978) Sleep and aminophylline treatment of apnea in preterm infants. European Journal of Pediatrics, 128, 145-149.
36. King DM, Heeley AE, Kuzemko FA. (1979) Half-life of theophylline in the preterm baby with apneic attacks. Archives of Disease in Childhood, 54, 238-239.
37. Brazier JL, Renaud H, Ribon B, Salle BL. (1979) Plasma xanthine levels in low birthweight infants treated or not treated with theophylline. Archives of Disease in Childhood, 54, 194-199.
38. Jones RAK, Baillie E. (1979) Dosage schedule for intravenous aminophylline based on pharmacokinetic studies. Archives of Disease in Childhood, 54, 190-193.
39. Hilligoss DM, Jusko WJ, Koup JR. (1980) Factors affecting theophylline pharmacokinetics in premature infants with apnea. Developmental Pharmacology and Therapeutics, 1, 6-15.
40. Hendeles L, Weinberger M. (1983) Theophylline: a state of the art review. Pharmacotherapy, 3, 2-44.
41. Crowley JJ, Cusack BJ, Jue SG, Koup JR, Park BK, Vestal RE. (1988) Ageing and drug interactions. II. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. Journal of Pharmacology and Experimental Therapeutics, 245, 513-523.
42. Randolph WC, Seaman JJ, Dickson B, Peace KE, Frank WO, Young MD. (1986) The effect of age on theophylline clearance in normal subjects. British Journal of Clinical Pharmacology, 22, 603-605.
43. Au WYW, Dutt AK, DeSoyza N. (1985) Theophylline kinetics in chronic obstructive airway disease in the elderly. Clinical Pharmacology and Therapeutics, 37, 472-478.
44. Vestal RE, Cusack BJ, Mercer GD, Dawson GW, Park BK. (1987) Ageing and drug interaction. 1. Effect of cimetidine and smoking on the oxidation of theophylline and cortisol in healthy men. Journal of Pharmacology and Experimental Therapeutics, 241, 488-500.
45. Shin SG, Juan D, Rammohan M. (1988) Theophylline pharmacokinetics in normal elderly subjects. Clinical Pharmacology and Therapeutics, 44, 522-530.
46. Aranda JV, Cook CE, Gorman W, et al. (1979) Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. Journal of Pediatrics, 94, 663-668.
47. Boutroy MJ, Vert P, Rover RJ, Monin P, Royer-Morrot MJ. (1979) Caffeine, a metabolite of theophylline during the treatment of apnea in the premature infant. Journal of Pediatrics, 94, 996-998.
48. Gorodischer R, Karplus M. (1982) Pharmacokinetic aspects of caffeine in premature infants with apnoea. European Journal of Clinical Pharmacology, 22, 47-52.
49. Le Guennec JC, Billon B, Pare C. (1985) Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding. Pediatrics, 76, 834-840.
50. Aranda JV, Collinge JM, Zinman R, Watters G. (1979) Maturation of caffeine elimination in infancy. Archives of Disease in Childhood, 54, 946-949.
51. Blanchard J, Sawers SJ. (1983) Comparative pharmacokinetics of caffeine in young and elderly men. Journal of Pharmacokinetics and Biopharmaceutics, 11, 109-126.
52. Tassaneeyakul W, Veronese ME, Birkett DJ, et al. (1992) Co-regulation of phenytoin and tolbutamide metabolism in humans. British Journal of Clinical Pharmacology, 34, 494-498.
53. Rechens A. (1979) Clinical pharmacokinetics of phenytoin. Clinical Pharmacokinetics, 4, 153-169.
54. Chiba K, Ishizaki T, Miura H, Minagawa K. (1980) Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient. Journal of Pediatrics, 96, 479-484.
55. Bourgeois BFD, Dodson WE. (1983) Phenytoin elimination in newborns. Newrology, 33, 173-178.
56. Bach B, Hansen JM, Kampmann JP, Rasmussen SN, Skovsted L. (1981) Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clinical Pharmacokinetics, 6, 389-96.
57. Greenblatt DJ, Abernethy DR, Matlis R, Harmatz JS, Shader RI. (1984) Absorption and disposition of ibuprofen in the elderly. Arthritis and Rheumatism, 27, 1066-1069.
58. Kupper A, Branch RA. (1985) Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clinical Pharmacology and Therapeutics, 38, 414-418.
59. Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L. (1990) Slow omeprazole metabolizer are also poor S-mephenytoin hydroxylators. Therapeutic Drug Monitoring, 12, 415-416.
60. Buchanan N. (1987) Pediatric clinical pharmacology and therapeutics. In: Speight TM, ed. Drug Treatment, 3rd edn. New Zealand: ADIS Press, 118-159.
61. Rowland M, Tozer TN. (1995) Age and weight. In: Rowland M, Tozer TN, eds. Clinical Pharmacokinetics: Concepts and Applications, 3rd edn. U.S.A: Williams and Wilkins, 230-247.
62. Greenblatt DJ, Allen MD, Harmatz JS, Shader RI. (1980) Diazepam disposition determinants. Clinical Pharmacology and Therapeutics, 27, 301-312.
63. Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR. (1975) The effects of age and liver disease on the disposition and elimination of diazepam in adult man. Journal of Clinical Investigation, 55, 347-359.
64. Macklon AF, Barton M, James O, Rawlins MD. (1980) The effect of age on the pharmacokinetics of diazepam. Clinical Science, 59, 479-483.
65. Divoll M, Greenblatt DJ, Ochs HR, Shader RI. (1983) Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. Anesthesia and Analgesia, 62, 1-8.
66. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. (1990) The hydroxylation polymorphisms of debrisoquine and mephenytoin in European population. European Journal of Clinical Pharmacology, 39, 533-537.
67. Treluyer JC, Jacqz-Aigrain E, Alvarez F, Gresteil T. (1991) Expression of CYP2D6 in developing human liver. European Journal of Biochemistry, 202, 583-588.
68. Ratanasavanh D, Beaune P, Morel F, Flinois JP, Guengerich FP, Guillouzo A. (1991) Intraloubular distribution and quantitation of cytochrome P-450 enzymes in human liver as a function of age. Hepatology, 13, 1142-1151.
69. Ogura C, Kishimoto A, Mizukawa R, Hazama H, Honma H, Kawahara K. (1983) Age differences in effects on blood pressure, flicker fusion frequency, salivation and pharmacokinetics of single oral doses of dothiepin and amitriptyline. European Journal of Clinical Pharmacology, 25, 811-814.
70. Schulz P, Turner-Tamiyasu K, Smith C, Giacomini KM, Blaschke TF. (1983) Amitriptyline disposition in young and elderly normal men. Clinical Pharmacology and Therapeutics, 33, 360-366.
71. Dawling S, Crome P, Braithwaite R. (1980) Pharmacokinetics of single oral doses of nortriptyline in depressed elderly hospital patients and young healthy volunteers. Clinical Pharmacokinetics, 5, 394-401.
72. Koop DR. (1942) Oxidative and reductive metabolism by cytochrome P450, 2E1. FASEB Journal, 6, 724-730.
73. Miller RP, Roberts RJ, Fischer LJ. (1976) Acetaminophen elimination kinetics in neonates, children, and adults. Clinical Pharmacology and Therapeutics, 19, 284-294.
74. Alam SN, Roberts RJ, Fischer LJ. (1977) Age-related differences in salicylamide and acetaminophen conjugation in man. Journal of Pediatrics, 90, 130-135.
75. Triggs EJ, Nation RL. (1975) Pharmacokinetics in the aged: a review. Journal of Pharmacokinetics and Biopharmaceutics, 3, 387-418.
76. Yamazaki H, Guo Z, Guengerich P. (1995) Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation. Drug Metabolism and Disposition, 23, 438-440.
77. Fulton B, James O, Rawlins MD. (1979) The influence of age on the pharmacokinetics of paracetamol. British Journal of Clinical Pharmacology, 1, 418P.
78. Divoll M, Greenblatt DJ, Ameer B, Abernethy DR. (1982) Effect of food on acetaminophen absorption in young and elderly subjects. Journal of Clinical Pharmacology, 22, 571-576.
79. Divoll M, Ameer B, Abernethy DR, Greenblatt DJ. (1982) Age does not alter acetaminophen absorption. Journal of the American Geriatrics Society, 30, 240-244.
80. Divoll M, Abernethy DR, Ameer B, Greenblatt DJ. (1982) Acetaminophen kinetics in the elderly. Clinical Pharmacology and Therapeutics, 31, 151-156.
81. Moltke LL, Greenblatt DJ, Schmider J, Harmats J, Schader R. (1995) Meatabolism of drugs by cytochrome P450, 3A isoforms. Clinical Pharmacokinetics, 29(Suppl. 1), 33-44.
82. Abernethy DR, Greenblatt DJ. (1983) Impairment of lidocaine clearance in elderly male subjects. Journal of Cardiovascular Pharmacology, 5, 1093-1096.
83. Nation RL, Triggs EJ, Selig M. (1977) Lignocaine kinetics in cardiac patients and aged subjects. British Journal of Clinical Pharmacology, 4, 439-448.
84. Cusack B, O'Malley K, Lavan J, Noel J, Kelly JG. (1985) Protein binding and disposition of lignocaine in the elderly. European Journal of Clinical Pharmacology, 29, 323-329.
85. Jonson C, Beekman R, Kostyshak D, Nguyen R, Oh D, Amidon G. (1991) Pharmacokinetics and pharmacodynamics of nifedipine in children with brancho-pulmonary dysplasia and pulmonary hypertension. Pediatric Research, 29, 500-503.
86. Robertson DR, Waller DG, Renwick AG, George CF. (1988) Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. British Journal of Clinical Pharmacology, 25, 297-305.
87. Collier PS, Kawar P, Gamble JAS, Dundee JW. (1982) Influence of age on pharmacokinetics of midazolam. British Journal of Clinical Pharmacology, 13, 602P.
88. Avram MJ, Fragen RJ, Caldwell NJ. (1983) Midazolam kinetics in women of two age groups. Clinical Pharmacology and Therapeutics, 34, 505-508.
89. Eller MG, Walker BJ, Westmark PA, et al. (1992) Pharmacokinetics of terfenadine in healthy elderly subjects. Journal of Clinical Pharmacology, 32, 267-271.
90. Tanaka EC, Breimer DD. (1997) In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease. Journal of Clinical Pharmacy and Therapeutics, 22, C237-C249.
91. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. (1996) Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochromo P450 enzymes catalying 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clinical Pharmacology and Therapeutics, 59, 613-623.
92. Nakamura M, Tanaka E, Misawa S, Shimada T, Imaoka S, Funae Y. (1994) Trimethadione metabolism, a useful indicator for assessing hepatic drug-oxidizing capacity. Biochemical Pharmacology, 47, 247-251.
93. Kurata N, Nishimura Y, Inaba T, Fischer N, Iwase M, Yasuhara H. (1997) Estimation of the human hepatic microsomal cytochrome P-450 species responsible to the trimethadione metabolism. Japanese Journal of Pharmacology, 73, 115.
94. Crom WR, Relling MV, Christensen ML, Rivera GK, Evans WE. (1991) Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. Clinical Pharmacology and Therapeutics, 50, 132-140.
95. Greenblatt DJ, Divoll MK, Harmatz JS, Shader RI. (1988) Antipyrine absorption and disposition in the elderly. Pharmacology, 36, 125-133.
96. Swift CG, Homeida M, Halliwell M, Roberts CJ. (1978) Antipyrine disposition and liver size in the elderly. European Journal of Clinical Pharmacology, 14, 149-152.
97. Salem SA, Rajjayabun P, Shepherd AM, Stevenson IH. (1978) Reduced induction of drug metabolism in the elderly. Age and Ageing, 7, 68-73.
98. Vestal RE, Wood AJ. (1980) Influence of age and smoking on drug kinetics in man: studies using model compounds. Clinical Pharmacokinetics, 5, 309-319.
99. Divoll M, Greenblatt DJ, Abernethy DR, Shader RI. (1982) Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. Journal of the American Geriatrics Society, 30, 684-689.
100. Nakamura H, Tanaka E, Ishikawa A, Fukao K, Tsuji K, Ohkawa H. (1998) Age-related changes in hepatic drug-oxidizing activity using trimethadione as a probe drug in human. Hepatology Research, 12, 85-92.